Cartesian Therapeutics’ Post

In a recent interview with Innovations in Pharmaceutical Technology Yama Abassi from Agilent Technologies spoke about the evolution of immune-oncology, gaps in existing cell analysis tools, and his outlook of adoptive cell therapies in the next decade. Read the article: Real time cell analysis (iptonline.com)

Very interesting white paper on the topic of dose optimisation in oncology and the challenges that still need to be addressed

PD-(L)1 Inhibitors Top Abstracts about to reveal at ASCO 2024 At ASCO 2024, leading pharmaceutical giants including AstraZeneca, Merck, Bristol Myers Squibb, BeiGene, AkesoBio, Hengrui Pharma Co.,Ltd, and Qilu Pharmaceuticals are poised to unveil initial, updated, and final findings. The forthcoming session generates high anticipation as it will reveal primary results from the Phase III CheckMate-9DW study, aiming to introduce a potential treatment avenue for enhancing outcomes in hepatocellular cancer, potentially surpassing established tyrosine kinase inhibitors. Notably, results from bi-specific PD-1 inhibitors like Acasunlimab (PD-1 X 4-1BB) and IBI363 (PD-1 and IL-2) will draw considerable attention. Moreover, insights from Chinese pharmaceutical companies are eagerly awaited as well. Unlock Exclusive Expert Insights and Comprehensive Analysis of ASCO 2024 with DelveInsight Business Research LLP @ https://lnkd.in/g-Qht2Qp #ASCO2024 #PharmaUpdates #ClinicalTrials #CheckMate9DW #HepatocellularCancer #BiSpecificInhibitors #MedicalResearch #CancerTreatment #BiotechNews #ChinesePharma

Over the years, various big pharmaceutical players have contributed to the market’s evolution by expanding their respective product portfolios and partnering with other key players. Check out the latest report by Roots Analysis on Bispecific Antibodies Market at https://lnkd.in/gTCWpZrn Some of the players listed in our report include Novartis NovalGen Multitude Therapeutics Molecular Partners Marengo Therapeutics MacroGenics, Inc. Light Chain Bioscience | Novimmune SA LEO Pharma Learn more about Roots Analysis consulting services: https://lnkd.in/dyfAawqZ #BispecificAntibody #BispecificAntibodies #ApprovedBispecificAntibodies #BispecificAntibodyMarket #RootsAnalysis

PD-(L)1 Inhibitors Top Abstracts about to reveal at ASCO 2024 At ASCO 2024, leading pharmaceutical giants including AstraZeneca, Merck Healthcare, Bristol Myers Squibb, BeiGene, Akeso, Hengrui Pharma Co.,Ltd, and Qilu Pharmaceuticals are poised to unveil initial, updated, and final findings. The forthcoming session generates high anticipation as it will reveal primary results from the Phase III CheckMate-9DW study, aiming to introduce a potential treatment avenue for enhancing outcomes in hepatocellular cancer, potentially surpassing established tyrosine kinase inhibitors. Notably, results from bi-specific PD-1 inhibitors like Acasunlimab (PD-1 X 4-1BB) and IBI363 (PD-1 and IL-2) will draw considerable attention. Moreover, insights from Chinese pharmaceutical companies are eagerly awaited as well. Unlock Exclusive Expert Insights and Comprehensive Analysis of ASCO 2024 with DelveInsight Business Research LLP - https://lnkd.in/gb4amxnj #ASCO24 #ASCO2024 #PharmaUpdates #ClinicalTrials #CheckMate9DW #HepatocellularCancer #BiSpecificInhibitors #MedicalResearch #CancerTreatment #BiotechNews #ChinesePharma #pd1 #inhibitors #Acasunlimab

Curia biologics is attending AACR in SD in April. We support discovery on complex biologics and ADCs. Please schedule a meeting with us to discuss your biologics needs and meet our experts PM or Roger.wong@curiaglobal.com Check out our poster too on antibody discovery (details below). #aacr #mab #antibodydiscovery #antibodytherapeutics #ADCs #biologicsdiscovery

DelveInsight Evaluates a Robust Atypical Teratoid Rhabdoid Tumors Clinical Trial as 6+ Influential Pharma Companies to Set Foot in the 7MM: The Atypical Teratoid Rhabdoid Tumors Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Atypical Teratoid Rhabdoid Tumors treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical … Continue reading → #HealthMedicine #PharmaceuticalsBiotech #Services

Innovative pharmaceutical products have become increasingly personalized, especially in oncology. As a result, the use of certain medicinal products is dependent on the presence of specific biomarkers in a patient. #pharmaceutical #clinicaltrials

The 10 highest value R&D projects in biopharma - Fierce Pharma 1. Sotatercept Company: Merck & Co. Status: Phase 3/Filed Indication: Pulmonary arterial hypertension Worldwide product revenues in 2028: $2.6 billion Today’s net present value: $11.6 billion Estimated launch: Early 2024 2. Datopotamab deruxtecan Company: Daiichi Sankyo and AstraZeneca Status: Phase 3 Indication: Lung cancer Worldwide product revenues 2028: $2.6 billion Today’s net present value: $11.5 billion Estimated launch: N/A 3. CagriSema Company: Novo Nordisk Status: Phase 3 Indication: Obesity Worldwide product revenues 2028: $1.9 billion Today’s net present value: $10.3 billion Estimated launch: N/A 4. Donanemab Company: Eli Lilly Status: Phase 3/Filed Indication: Alzheimer’s Worldwide product revenues 2028: $2.1 billion Today’s net present value: $8.8 billion Estimated launch: FDA decision due end of 2023donanemab 5. KarXT Company: Karuna Therapeutics and Zai Lab 6. mRNA-1647 Company: Moderna 7. Iptacopan Company: Novartis 8. Resmetirom Company: Madrigal Pharmaceuticals 9. Aficamten Company: Cytokinetics 10. Tiragolumab Company: Roche and Chugai Pharmaceutical https://lnkd.in/e9PjPCdQ

Hematologic Malignancies Key Abstracts to watch during ASCO 2024. Leading companies such as Janssen Inc., Novartis, Genmab, Pfizer, Innate Pharma, and Sanofi are preparing to unveil their latest data and final analyses at the upcoming conference. The spotlight will be on key abstracts expected to make a lasting impact, generating significant interest and discussion throughout the event. In the last decade, the treatment options for hematologic malignancies have undergone significant expansion, notably with the advent of novel CAR T-cell therapies. These groundbreaking treatments have greatly enhanced patient outcomes. However, clinicians frequently encounter difficulties in identifying suitable candidates for these therapies, particularly among elderly individuals. Stay tuned with DelveInsight Business Research LLP for all the latest advancement in the Hematologic Malignancies set to be presented during the meeting @ https://lnkd.in/gd3txwQP #HematologicMalignancies #CARTTherapies #JanssenInnovates #NovartisResearch #GenmabAdvances #PfizerResearch #InnatePharmaUpdates #SanofiInnovation #ConferenceSpotlight #AbstractAnalysis #HematologyConference #ElderlyPatients #PersonalizedTherapy #ClinicalResearch #MedicalAdvancements